We believe this site might serve you best:

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Dr. Terry Riss, Promega Corporation, Madison

Nanoluc® Luciferase: A Smaller, Brighter & More Versatile Luciferase Reporter

Abstract

NanoLuc® Luciferase, a 19kDa, monomeric luciferase gives a brighter signal and enables more sensitive measurement. The NanoLuc®/Nano-Glo® Assay is ~100-fold brighter than either firefly or Renilla luciferase in vitro and in cells. This seminar will introduce the characteristics and uses of NanoLuc® Luciferase and considerations for choosing Firefly or NanoLuc® Luciferase. Applications of NanoLuc® Luciferase as a fusion partner will be described including protein translocation and degradation.

Dr Terry Riss started the Cell Biology program at Promega Corporation in 1990. He has since held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Specialist, Cell Health involved in outreach educational training activities. Dr. Riss regularly participates in NIH study sections reviewing HTS grants and is co-editor of the cell culture assays section of the Assay Guidance Manual hosted by the NIH.

Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom